<- Go Home
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Market Cap
$30.7M
Volume
492.2K
Cash and Equivalents
$6.6M
EBITDA
-$15.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.55
52 Week Low
$0.42
Dividend
N/A
Price / Book Value
1.88
Price / Earnings
-1.67
Price / Tangible Book Value
1.88
Enterprise Value
$11.7M
Enterprise Value / EBITDA
-0.76
Operating Income
-$15.4M
Return on Equity
83.81%
Return on Assets
-43.37
Cash and Short Term Investments
$19.4M
Debt
$342.0K
Equity
$16.3M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A